	US 12,233,127 B2
	Human monoclonal antibodies to a new universal influenza A hemagglutinin head domain epitope
James E. Crowe, Jr., Nashville, TN (US)
Assigned to Vanderbilt University, Nashville, TN (US)
Appl. No. 17/270,115
Filed by Vanderbilt University, Nashville, TN (US)
PCT Filed Aug. 22, 2019, PCT No. PCT/US2019/047606 § 371(c)(1), (2) Date Feb. 22, 2021, PCT Pub. No. WO2020/041540, PCT Pub. Date Feb. 27, 2020.
Claims priority of provisional application 62/848,301, filed on May 15, 2019.
Claims priority of provisional application 62/721,675, filed on Aug. 23, 2018.
Prior Publication US 2021/0252150 A1, Aug. 19, 2021
Int. Cl. A61K 39/42 (2006.01); A61P 31/16 (2006.01); C07K 16/10 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/42 (2013.01) [A61P 31/16 (2018.01); C07K 16/1018 (2013.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); G01N 2333/11 (2013.01)]

16 Claims

1. A method of treating a subject infected with influenza A virus or reducing the likelihood of infection of a subject at risk of contracting influenza A virus, comprising administering to said subject an antibody or antibody fragment having heavy chain CDR1-3 sequences and light chain CDR1-3 sequences of SEQ ID NOS: 17-19 and SEQ ID NOS: 29-31, respectively, or administering an RNA or DNA sequence or vector encoding the antibody or antibody fragment.